|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV).
|
29851985 |
2018 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The main purpose of this study was to provide and validate a simple, rapid, and inexpensive polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique for genotyping of ITPA rs1127354 and rs7270101 polymorphisms in chronic HCV-infected patients.
|
29660762 |
2018 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that IPTA rs1127354 non-genotype CC, HCV genotype, a baseline HCV RNA level <4 × 10 IU/mL, IL-28B rs12979860 genotype CC, and low liver fibrosis were independent predictors for SVR during the combination therapy.IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the SVR to PEG-IFN plus ribavirin combination therapy in Chinese HCV-infected patients.
|
28723780 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of two functional polymorphisms (rs1127354 and rs7270101) of the inosine triphosphatase (ITPA) gene associated with ribavirin-induced hemolytic anemia (RIHA) during antiviral therapy for hepatitis C virus (HCV) infection varies by ethnicity.
|
28233743 |
2017 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV).
|
27349952 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.
|
27822709 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hb levels and protect against hemolytic anemia during RBV-containing regimens for HCV.
|
28480960 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.(Gut Liver, 2015;9214-223).
|
25287171 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
|
26071337 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection.
|
26250055 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection.
|
26441325 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown.
|
26650626 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a meta-analysis of all eligible studies assessing ITPA gene polymorphisms related to RBV-induced hemolytic anemia in HCV-infected patients published in PubMed, Embase and the Cochrane library prior to the end of 2014.
|
26438033 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty patients infected with hepatitis C virus (HCV) genotype 1 and starting anti-HCV therapy with telaprevir in combination with pegylated-IFN/ribavirin were prospectively evaluated for SNPs at the SLC29A1 gene and inosine triphosphatase (ITPA) genes using a real-time PCR system.
|
25583751 |
2015 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Presence of HCV RNA did not influence ITPase activity.
|
25968438 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 66 patients with HCV genotype 1 who had a late viral response (LVR) to 72-week treatment of pegylated-interferon and RBV, we examined the factors that determined the outcome, including single nucleotide polymorphisms of interleukin-28B and inosine triphosphatase (ITPA) genes.
|
23980585 |
2014 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that patients (63%) being homozygous for both major alleles, leading to normal ITPase activity, may benefit more from the addition of ribavirin to present and future treatment regimens for HCV in spite of concomitant increased risk of anemia.
|
24519039 |
2014 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for RBV dose reduction in Egyptian HCV patients.
|
23538996 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.
|
23195617 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin.
|
23301546 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy.
|
23201294 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.
|
23918534 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the ITPA gene have been associated with anemia during combination therapy in hepatitis C virus (HCV)-monoinfected patients.
|
22430973 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genotypes of the ITPA rs1127354 single nucleotide polymorphism were determined in 179 patients with HCV infection.
|
22052220 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaemia is a common side effect of ribavirin (RBV) which is used for the treatment of hepatitis C. Inosine triphosphatase gene polymorphism (C to A) protects against RBV-induced anaemia.
|
22571903 |
2012 |